APRE Aprea Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why APRE matters now
Aprea Therapeutics, Inc. (APRE) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.75 with +2.34% on the session and $4.8M in market capitalization; recent performance reads 1-month -10.63% and YTD -16.18%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-3.3M, and EPS of $-0.43. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -263.1%.
The latest indexable market news headline is "Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Seizinger Bernd R. filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.13
P/S
39.32
EV/EBITDA
3.50
DCF Value
$2.13
FCF Yield
-263.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
-1523.6%
Operating Margin
-10649.9%
Net Margin
-10121.7%
ROE
-59.5%
ROA
-24.8%
ROIC
-29.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-3.3M | $-0.43 |
| Q4 2025 | $0.00 | $-2.5M | $-0.32 |
| FY 2025 | $0.00 | $-12.6M | $-1.93 |
| Q3 2025 | $0.00 | $-3.0M | $-0.47 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.56
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.